Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC trimmed its holdings in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 20.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 696,797 shares of the specialty pharmaceutical company’s stock after selling 182,276 shares during the period. AQR Capital Management LLC owned approximately 5.37% of Eagle Pharmaceuticals worth $3,902,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of EGRX. Los Angeles Capital Management LLC lifted its stake in Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 100,470 shares during the period. DGS Capital Management LLC increased its holdings in shares of Eagle Pharmaceuticals by 442.5% during the 1st quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock valued at $325,000 after purchasing an additional 50,525 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at approximately $145,000. AIGH Capital Management LLC increased its holdings in shares of Eagle Pharmaceuticals by 2.1% during the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after purchasing an additional 25,000 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at approximately $113,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Eagle Pharmaceuticals in a report on Friday. They set a “hold” rating for the company.

Eagle Pharmaceuticals Price Performance

NASDAQ:EGRX opened at $0.90 on Friday. The firm has a market cap of $11.69 million, a price-to-earnings ratio of 0.76 and a beta of 0.51. The company has a 50 day moving average price of $4.19 and a 200-day moving average price of $4.53. Eagle Pharmaceuticals, Inc. has a 1-year low of $0.75 and a 1-year high of $14.78.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.